U.S. Markets closed

Ideaya Biosciences' stock opened 40% above its IPO price, then pared most of its gains

Tomi Kilgore

Shares of Ideaya Biosciences Inc. soared in its public debut, then pared most of its gains, biotechnology company focused on cancer treatments debuted as the broader stock market slumped. The first trade in Ideaya's stock was at $14.00 at 10:57 a.m. Eastern, 40% above the $10 initial public offering price. The stock was last 9.9% above the IPO price at $10.99. Meanwhile, the iShares Nasdaq Biotechnology ETF was down 1.3%, the Renaissance IPO ETF was shedding 2.3% and the S&P 500 was losing 1.7%. The company sold 5 million shares in the IPO to raise $50 million, as the IPO pricing implied a market capitalization of about $194.8 million. The company recorded a net loss of $34.3 million and no sales in 2018, compared with a 2017 loss of $11.9 million on no revenue.